Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs) | Bentham Science
Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs)

Author(s): Sho-ichi Yamagishi and Takanori Matsui

Volume 11, Issue 7, 2010

Page: [875 - 881] Pages: 7

DOI: 10.2174/138945010791320827

Price: $65

Open Access Journals Promotions 2
Abstract

Accelerated atherosclerosis is the leading cause of coronary heart disease and stroke, which could account for high mortality rates in patients with diabetes. Although several hyperglycemia-elicited metabolic and hemodynamic derangements have been implicated in the pathogenesis of cardiovascular disease (CVD) in diabetes, the process of formation and accumulation of advanced glycation end products (AGEs) and their mode of action are most compatible with the phenomenon metabolic memory and legacy effect, that is, vascular stresses during the diabetic exposure have persisted after glucose normalization. Further, there is a growing body of evidence that a receptor for AGEs (RAGE) is involved in signal transduction of AGEs in a variety of cells. In this paper, we review the role of the AGE-RAGE system in accelerated atherosclerosis, especially focusing on smooth muscle cell pathophysiology, and also discuss the possibility that the AGE/RAGE axis could be a potential therapeutic target for prevention of CVD in patients with diabetes.

Keywords: AGEs, oxidative stress, RAGE, cardiovascular disease


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy